Compare Charles River Laboratories Intl. Inc (CRL) vs Davita Inc (DVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Davita Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $282.01 (market cap $13.22B), while Davita Inc trades at $179.02 (market cap $11.72B). The key difference: Charles River Laboratories Intl. Inc and Davita Inc are close in size by market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals.
| CRL | DVA | |
|---|---|---|
Market Cap | $13.22B | $11.72B |
Sector | Health | Health |
52-Week High | $282.00 | $240.96 |
52-Week Low | $145.57 | $103.87 |
Enterprise Value | $16.06B | $24.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $267.49, up 0.75% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.02 versus $2.77 expected, and raised full-year guidance. Despite negative net income margins and high valuation multiples, analyst sentiment remains overwhelmingly positive with 72% buy ratings.
CRL shows operational strength with consistent earnings beats and improved demand, yet faces risks from high debt and profitability challenges. The consensus price target of $277.29 suggests modest upside, but investors must weigh growth prospects against valuation concerns and macroeconomic pressures on biotech spending.
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →
